AcceleTrial

AcceleTrial is a clinical trial site activation platform developed by LINEA System. It is designed for sponsors and CROs managing multi-site study startup in oncology, rare disease, CNS, and other therapeutic areas. The platform replaces fragmented tools — email threads, spreadsheets, and shared drives — with a single governed workspace that covers every stage from site selection through first patient enrolled, with the stated goal of compressing startup timelines by up to 50%.

AcceleTrial ingests a ranked site list from LINEA's Research Site Index (RSI) and runs it through an execution system that governs feasibility outreach, contract and budget management, regulatory document tracking, and milestone monitoring. Every action is logged with a timestamp and user record, and delays are flagged before they affect the overall timeline.

Workflow Stages

1. Site Selection: Sponsors upload a protocol document and AcceleTrial's AI automatically extracts therapeutic area, indication, phase, and enrollment targets. The system scores and ranks the full RSI against the protocol in real time, loading the ranked site list directly into the startup workspace without manual data entry.
2. Qualification: Each site moves through a structured qualification workflow. Sponsors and CROs review RSI scores, feasibility responses, and capacity data. Every approval or rejection is logged by timestamp and user, creating a fully auditable record of qualification decisions.
3. Feasibility Outreach: AcceleTrial automatically dispatches digital feasibility questionnaires to all selected sites. Responses are collected, scored against the protocol, and ranked within the platform, replacing manual coordination with automated outreach.
4. Contracts and Budgets: Budget negotiations, contract drafts, redlines, and executed agreements are all managed within the platform. Milestone-linked budget approvals, payment terms, and amendment tracking provide visibility to both sponsors and sites throughout the contracting process.
5. Regulatory Documents: IRB submissions, protocol amendments, essential document checklists, and regulatory correspondence are stored, versioned, and tracked against submission deadlines. The platform flags missing documents before they can delay startup.
6. Activation: Site initiation visits, enrollment readiness checks, and activation milestones are tracked in real time across the full site portfolio. SLA risks are surfaced in advance, giving operations teams time to intervene before timeline impact.

Platform Capabilities

• Role-Based Workspaces: Sponsor, CRO, and site teams each access a workspace tailored to their role and permission level. Document visibility, approval authority, and reporting views are governed by role assignment rather than email inclusion.
• Document Controls and Audit Trail: Every document version is tracked and every approval action is logged with timestamp and user identity. The complete audit trail is available for regulatory review at any point during the study.
• SLA Monitoring and Risk Flags: The platform tracks every contractual and regulatory milestone against its deadline and automatically flags sites that are falling behind, providing advance warning before delays become timeline risks.
• Portfolio Reporting and Visibility: A single dashboard displays study startup status across all sites, including contract progress, regulatory completeness, activation readiness, and enrollment projections, eliminating the need to manually assemble status updates from individual site coordinators.

Reported Metrics

• Up to 50% faster trial startup timeline
• 96% of sites approved and included
• Access to over 250,000 investigator records via the RSI
• End-to-end coverage from site selection to first patient enrolled

AcceleTrial is available via demo request, with sessions conducted using the requesting organization's specific therapeutic area, indication, and site portfolio size. The platform integrates with LINEA's Research Site Index as its upstream data source for site scoring and ranking.